Gangwon Techno Park (President Heo Jang-hyun) announced that it will participate in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10 (Wed) to 12 (Fri). .
Gangwon Technopark establishes industrial development strategies and policies suitable for the circumstances and characteristics of Gangwon-do, and is a regional innovation base organization that supports them. It is a public institution that supports and conducts joint research. In this regard, Gangwon Technopark is promoting corporate support projects and infrastructure creation as a leading organization for the ‘Hongcheon National Antibody Cluster’ in accordance with the bio policy of Gangwon-do and Hongcheon-gun.
The Hongcheon National Antibody Cluster is carrying out business support projects such as occupancy space, equipment and technology support, and human resource training to foster small and medium-sized venture companies related to the development of biopharmaceuticals such as antibody treatment and immunotherapy in Hongcheon-gun, Gangwon-do. Accordingly, we decided to participate in this exhibition to attract and promote related companies.
The Hongcheon National Antibody Cluster aims to advance the local industrial structure of Hongcheon-gun, integrates space, facilities, equipment, technology, manpower, and residential conditions for the early stage development and commercialization of biopharmaceuticals such as antibody treatments, and integrates start-ups and venture businesses. ‧We have a goal to develop. As for the business area, it will discover basic/original research and candidate substances, optimize and advance them, and then carry out non-clinical experiments or technology transfer.
Starting with the completion of the Neutralizing Antibody Treatment Development Support Center in the third quarter of 2023, the project will be promoted in earnest through the establishment of research facilities, equipment, and space for research and development of infectious diseases, as well as manpower support. As a similar project, the Immune Antibody Treatment Material Development Support Center is scheduled to begin construction in the third quarter of this year. In addition, through the Rapid Response Research Center for Future Infectious Diseases (BL3), a biosafety-grade research facility will be established for use by resident companies. plans to build them.
The Hongcheon National Antibody Cluster introduces and operates the latest biopharmaceutical development-related analysis equipment, such as Berkely Lights’ Beacon equipment for biopharmaceutical development.
An official said, “We are planning business support projects to strengthen the competitiveness of companies’ technologies, discover new original technologies, and support equipment utilization.” We are preparing to provide convenience.”
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.